Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Global R&D Heads Talk Superbugs, PROTACs And More

Risk Is Essential To Discovery

Executive Summary

A panel of R&D experts from Merck’s EMD Serono, Boehringer Ingelheim, Takeda and Hilleman Labs discuss technologies like PROTACs and multi-specific antibodies, a superbug that could cause more damage than COVID-19 and the need for harmonized regulation that recognizes risk is essential to discovery

You may also be interested in...



Pfizer's India MD On Funding Healthcare Startups

Pfizer’s India managing director, S Sridhar, talks to Scrip about funding startups focused on oncology and digital health, via the CSR route. Two such startups, SiCureMi and Tinkertech, are close to commercialization. Meanwhile, Pfizer's pact with MPP will allow the COVID-19 antiviral Paxlovid to find its way to India and 94 other low- and middle-income countries

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: CAR-Ts move into earlier treatment; Sanofi bets big on super antibodies; takeaways from the world’s largest dermatology conference; China moves towards imported COVID vaccines; and R&D experts discuss the superbug threat.

Accenture Sees AI Solutions For IDMP Compliance, Trial Efficiency

AI could help companies comply with regulations like GDPR and IDMP, apart from optimizing clinical trial processes, Accenture’s managing director leading R&D analytics in North America says, as he lists cases where the firm drove cost savings.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146132

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel